Analysts at H.C Wainwright initiated coverage on X T L Biopharmaceuticals Ltd (ADR) XTLB with a Buy rating.
The target price for XTL Biopharmaceuticals is set to $6.
XTL Biopharmaceuticals shares have dropped 30.58 percent over the past 52 weeks, while the S&P 500 index has surged 11.15 percent in the same period.
XTL Biopharmaceuticals' shares rose 14.14 percent to $2.30 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in